Larimar Therapeutics Inc. (LRMR)
NasdaqGM: LRMR
· Real-Time Price · USD
4.31
+0.00 (0.00%)
At close: Aug 12, 2026, 10:17 AM
Larimar Therapeutics Inc. (LRMR) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 2.95 |
| Market Cap | 447.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -172.6M |
| Beta | 0.75 |
| EPS (ttm) | -2.01 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.06 |
| P/B (ttm) | 3.53 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 5.29 |
| Volume | 160,210 |
| Avg. Volume (20D) | 2,122,893 |
| Open | 4.31 |
| Previous Close | 4.31 |
| Day's Range | 4.30 - 4.40 |
| 52-Week Range | 2.71 - 6.42 |
| Analyst | Strong Buy |
| Price Target | 12.5 (190.02%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania....
Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2014
Employees 71
Stock Exchange NasdaqGM
Ticker Symbol LRMR
Website https://www.larimartx.com
Financial Performance
In 2025, Larimar Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -165.67M, an increase of 105.54%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for LRMR stock is "Strong Buy". The 12-month stock price forecast is 12.5, which is upside of 190.02% from the latest price.
Stock ForecastsEarnings Surprise
Larimar Therapeutics has released their quarterly earnings on Aug 4, 2026:
Larimar Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2